1 / 35

Achalasia of the Esophagus

Achalasia of the Esophagus. Dr. Saleh M. Aldaqal MBBS, FRCSI,SBGS Assistant Professor and Consultant General And laparoscopic Surgery(France), Department of Surgery, Faculty of Medicine, King Abdulaziz University. www.dr-aldaqal.com. Introduction .

maalik
Download Presentation

Achalasia of the Esophagus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Achalasiaof the Esophagus Dr. Saleh M. Aldaqal MBBS, FRCSI,SBGS Assistant Professor and Consultant General And laparoscopic Surgery(France), Department of Surgery, Faculty of Medicine, King Abdulaziz University. www.dr-aldaqal.com

  2. Introduction • Primary esophageal motility disorder of unclear etiology. • Uncommon, but not rare. affecting approximately 1 in 100,000/ year in America, 5 in 100,ooo/year in Europe. • Equally in men and women. • Usually diagnosed between 20 and 50 years of age

  3. History • In 1672, Sir Thomas William first described the disease as “cardiospasm” and treated the problem with dilation using a whale sponge attached to a whale bone. • 1927A F Hurst named the disease achalasia, a Greek term meaning failure to relax.

  4. Etiology • Achalasia can be primary (idiopathic) or secondary. • Primaryachalasia :absence of inhibitory ganglion cells in the myenteric (Auerbach's) plexus of the esophagus. • ? Infectious agent, such as a virus, and its subsequent immune response.

  5. Etiology • The most common secondary cause of achalasia is Chagas' diseasea systemic disease caused by infestation by the protozoan Trypanosomacruzi. Chagas is transmitted to humans by the reduviid or “kissing bug” . • worldwide is considered to be the most common cause of achalasia.

  6. Diagnosis • The gold standard for diagnosis of achalasia is esophageal manometry. • Manometry is especially helpful in early disease state when other diagnostic evaluations appear normal.

  7. Diagnosis • Residual LES relaxation pressure to be the most accurate diagnostic manometric criteria. • A residual pressure of >12 mmHg had 92% sensitivity. • Aperistalsis, a residual pressure of >10 mmHg had 100% sensitivity and 100% positive predictive value .

  8. Diagnosis • High-Resolution manometry (HRM) and multichannel intraluminal impedance (MII) studies Normal Achalasia

  9. Treatment • Achalasia is an incurable disease and treatment is focused on relief of symptoms. • The goal of both surgical and nonsurgical treatment is to eliminate the outflow obstruction afforded by a nonrelaxing sphincter, relieve dysphagia, and maintain a barrier against gastroesophageal reflux.

  10. Pharmacologic treatment • Oral nitrates and calcium channel blockers, act to inhibit intramural neurons. • Poor outcomes and potentially harmful systemic effects, these agents are largely unreliable and unrealistic modalities for longterm symptom relief.

  11. Endoscopic injection of Botox • Injection of Botox into the LES aims to block release of acetylcholine from cholinergic neurons in an effort to lower both basal and residual LES pressures. • Short-lived, rarely results in substantial reduction in LES pressure, and, although dysphagia can be improved, often requires repeat injections for continued relief.

  12. Endoscopic injection of Botox • In a prospective randomized controlled trial comparing Botox injection (n = 40) with laparoscopic myotomy and partial fundoplication (n = 40), • Zaninotto and colleagues • 6 months after treatment dysphagia and regurgitation recurred in nearly half (45%) of those treated with Botox. • symptom-free at 2 years was considerably higher after myotomy (87.5%) than after Botox injection (34%).

  13. Endoscopic injection of Botox • It is now recognized that Botox injection creates an inflammatory reaction in the distal esophagus with consequent submucosal fibrosis, which can make subsequent surgical myotomy more difficult. • Botox should be reserved for those who are not surgical candidates.

  14. Pneumatic balloon dilation • Decreases esophageal outflow resistance by forceful “tearing” of the LES muscle fibers. • The most common balloon dilators in current use are the Rigiflexand Witzelpolyethylene balloons. • Rigiflex is a balloon on a catheter, which is placed using fluoroscopy, and the Witzelballoon is inserted while attached to the endoscope. Risk of perforation using the Rigiflex is about 3% and that of the Witzel is 6%.

  15. Pneumatic balloon dilation • Graded balloon dilation is begun using a 30-mm balloon as the initial dilator. • Repeat balloon dilation can be performed using progressively larger dilator sizes to 35 mm and 40 mm

  16. Pneumatic balloon dilation • The only prospective randomized trial comparing pneumatic dilation to surgical myotomywas reported by Csendes and colleagues from Chile. • They found that 100% of patients treated with myotomy (n = 19) had only mild or no dysphagia at a mean of 3.5 years, as compared with only 61% of those treated with balloon dilation (n = 18).

  17. Pneumatic balloon dilation • Two more recent evaluations byWest and colleagues • Retrospectively evaluated longterm outcomes of 125 achalasia patients followed prospectively for >5 years after pneumatic dilation. • In this experience, only 50% of patients had no or occasional (less than once per week) dysphagia at 5 years.

  18. Laparoscopic myotomy and partial fundoplication was superior to pneumatic dilation in newly diagnosed patients with achalasia.

  19. Surgical treatment • Esophageal myotomy for achalasia was first described by Ernest Heller in 1913. • In this operation, both the anterior and posterior lower esophageal sphincter muscle fibers were disrupted. • A modified version of this procedure, referred to today as the Heller myotomy, consists of a single anterior longitudinal myotomyand has become the standard operative technique. performed through either a thoracotomy or laparotomy.

  20. Thoracoscopic or laparoscopic. • Recent review of studies evaluating thoracoscopicmyotomy from 1993 to 2005 (n = 10 studies; 204 patients) and laparoscopic myotomy from 1995 to 2005 (n = 15 studies; 499 patients) by Abir and colleagues . • Symptom relief to occur in 76% versus 94% of patients, respectively. • Development of gastroesophageal reflux disease occurred in 35% of patients after thoracoscopicmyotomy and 13% of patients after laparoscopic myotomy.

  21. Fundoplication ? • An anterior partial fundoplication (Dor) • Anterior fundus is laid across the myotomy site and sewn to the cut edge of the esophageal myotomy with three or four interrupted sutures of 2-0 silk. • Highest stitch is taken through the crural pillar as an anchor to prevent torsion of the fundus.

  22. Fundoplication ? • Posterior partial fundoplication (Toupet), • The anterior fundus is brought to either side of the myotomy, and two columns of sutures are placed on either side, leaving the myotomy site bare and open

  23. Fundoplication ? • A recent prospective randomized study has put this issue to rest. • Richards and colleagues reported on 43achalasia patients randomized to laparoscopic Heller myotomywith and without Dorfundoplication. • Gastroesophageal reflux, defined by 24-hour distal esophageal acid exposure time >4.2%, • was present in 47.5% of patients undergoing Heller myotomy alone compared with 9.1% of patients undergoing Heller myotomy with partial fundoplication.

  24. Results of laparoscopic Heller myotomywith fundoplication • Complications average 10% to 15%, and commonly include pneumothorax, wound infection, and esophageal leak. • Mortality is uncommon, zero in most large published series. • Injury of the esophageal mucosa occurs in 0 to 14% of procedures and, when recognized and repaired, is rarely of clinical consequence.

  25. Results of laparoscopic Heller myotomywith fundoplication • Most published results report similar results. • More than 91% were symptom-free at a median of 2 years followup. • 90% probability of remaining asymptomatic at 5 years. • symptoms were found in 7% of patients <10 years, 23% of those 10 to 20 years, and 35% of patients >30 years postmyotomy.

  26. Outcomes predictors • Young patients (younger than 40 years) have been shown to respond less well to pneumatic dilation and are good candidates for primary myotomy. • Lowering resting LES pressure to near 10 mmHg post operative has been reported by several authors to substantially affect longterm success of surgery or pneumatic dilation.

  27. Extent of myotomy • Better symptomatic improvement and a lower incidence of recurrent dysphagia by increasing the distal extent of myotomy onto the proximal stomach from 1.5 cm to 3 cm • Postoperative 24-hour pH data showed that extension of the distal aspect of the myotomydid not result in a higher prevalence of gastroesophageal reflux.

  28. Persistent or recurrent symptoms • Mild to moderate symptoms of dysphagia, regurgitation, heartburn, and chest pain recur with time in as many as 15% to 20% of patients. • Lifestyle and behavioral changes or proton-pump inhibitor therapy

  29. Persistent or recurrent symptoms • Early failures are usually caused by failure to extend the myotomy far enough onto the stomach. • Late failures occur secondary to development of complicated gastroesophageal reflux with stricturing or Barrett's changes and disease progression

  30. Persistent or recurrent symptoms • Pneumatic dilation should be considered as the first-line treatment for patients with persistent dysphagia and that reoperation should be reserved for those who do not respond.

  31. THANK YOU

More Related